Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - A prospective study

Archives of Medical Science

Volumn 8, Issue 2, 2012, Pages 227-235

  Piotrowski, Grzegorz ^a   Gawor, Rafał ^a   Stasiak, Arkadiusz ^b   Gawor, Zenon ^a   Potemski, Piotr ^c   Banach, Maciej ^c  

^a M Kopernik Specialist District Hospital   (Poland)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Breast cancer; Cardiotoxicity; HER2 overexpression; Trastuzumab; Trastuzumab related cardiomyopathy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CONTROLLED STUDY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PROSPECTIVE STUDY; UNIVARIATE ANALYSIS;

EID: 84861462964     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.28549     Document Type: Article

References (39)

1. Hudziak RM, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci 1987; 84: 7159-63.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82. (Pubitemid 17231334)
3. Force T, Krause DS, Van Etten. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332-44. (Pubitemid 46652481)
4. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2 positive early. Oncologist 2006; 11 Suppl 1: 4-12.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72. (Pubitemid 41464705)
6. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-20. (Pubitemid 43290919)
7. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366-73.
8. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-21. (Pubitemid 34177427)
9. Mackey JR, Clemons M, Cote MA, et al. Cardiac management adjuvant trastuzumab therapy: recommendation of the Canadian Working Group. Current Oncol 2008; 15: 24-35.
10. Jones AL, Barlow M, Barrett-Lee PJ, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009; 100: 684-92.
11. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of chocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiography 2005; 18: 1440-6.
12. Carver JR Carver JR. Management of trastuzumab-related cardiac dysfunction. Prog Cardiovasc Dis 2010; 53: 130-9.
13. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). The task force for the diagnosis and treatment of CHF of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-40.
14. Wysocki PJ, Hutka M. Cardiotoxicity of 5-fluorouracil in a young colorectal cancer patient - case report and review of literature. Arch Med Sci 2009; 5: 277-80.
15. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapyinduced cardiotoxicity. The role of troponins and other markers. Drug Saf 2002; 25: 301-11. (Pubitemid 34634269)
16. Olin RL, Desai SS, Fox K Davidson Rl. Non-myopathic cardiac events in two patients treated with trastuzumab. Breast J 2007; 13: 211-2. (Pubitemid 46280618)
17. ATu CM, Chu KM, Yang SP, Cheng SM, Wang WB. Trastuzumab (Herceptin)-associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: a case report and literature review. Am J Emerg Med 2009; 27: 903e1-3.
18. Oliveira M, Nave M, Gil N, Passos-Coelho JL. Sudden death during adjuvant trastuzumab therapy of breast cancer. Ann Oncol 2010; 21: 901.
19. Slamon D, Eiermann W, Robert N, -006 oboB BCIRG 006:2nd interim analysis chase III randomised trial comparing doxorubicine and cyclophosphamid followed by docetaxel (AC/T) with doxorubicine and cyclo phosphamid followed by docetaxel and trastuzumab (AC/ETH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. In: Proceedings of San Antonio breast cancer symposium (SABCS): 2006, San Antonio. Breast Cancer Research and Treatment.
20. Wadhwa D, Fallah-Rad N, Grenier D, et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 2009; 117: 357-64.
21. Tarantini L, Cioffi G, Gori S, et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 2012; 18: 113-9.
22. McArthur HL, Chia S. Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med 2007; 357: 94-5.
23. Guarneri V, Lenihan DJ, Valero V, et al. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer 2004; 90: 36-40.
24. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 1800-8. (Pubitemid 34273269)
25. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84. (Pubitemid 41464706)
26. Kelly H, Kimmick G, Dees EC, et al. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clin Breast Cancer 2006; 7: 237-43. (Pubitemid 44445736)
27. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in nodepositive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23: 7811-9. (Pubitemid 46657378)
28. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26: 1231-8.
29. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007; 50: 1435-41. (Pubitemid 47494586)
30. Jones LW, Courneya KS, Fairey AS, Mackey JR. Effects of an oncologist's recommendation to exercise on self-reported exercise behavior in newly diagnosed breast cancer survivors: a single-blind, randomized controlled trial. Ann Behav Med 2004; 28: 105-13. (Pubitemid 39313356)
31. Irwin ML, McTiernan A, Baumgartner RN, et al. Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 2005; 23: 774-82. (Pubitemid 46224176)
32. Clarke CA, Purdie DM, Glaser SL. Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors. BMC Cancer 2006; 6: 170-81.
33. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-38. (Pubitemid 36459468)
34. Hosseini M, Houshmand M, Ebrahimi A. MTHFR polymorphisms and breast cancer risk. Arch Med Sci 2011; 7: 134-7.
35. Gluba A, Pietrucha T, Banach M, Piotrowski G, Rysz J. The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Angiology 2010; 61: 157-65.
36. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23: 7820-6. (Pubitemid 46657379)
37. Pentassuglia L, Graf M, Lane H, et al. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp Cell Res 2009; 315: 1302-12.
38. Singh KK, Shukla PC, Quan A, et al. Herceptin, a re combinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death. Biochem Biophys Res Commun 2011; 411: 421-6.
39. Verma S, Ewer MS. Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer? Ann Oncol 2011; 22: 1011-8.